Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

119 results about "Receptor agonist activity" patented technology

Interacts with receptors such that the proportion of receptors in the active form is increased. [GOC:ceb, ISBN:0198506732]

Preparation and application of whey protein source hypoglycemic peptide with GLP-1 receptor agonist activity

PendingCN120699089AMetabolism disorderTetrapeptide ingredientsEnteroendocrine cellInsulin humulin
The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.
Owner:CHINA AGRI UNIV

Small-molecule compound having GLP-1 receptor agonist activity and use thereof

A GLP-1 receptor agonist having a structure of formula I, a pharmaceutically acceptable salt or a stereoisomer. Compared with LY3502970, the compound has excellent drug-like properties.
Owner:HINOVA PHARM INC

Pharmaceutical composition containing a pyrazolopyridine derivative having GLP-1 receptor agonist activity

To provide pharmaceutical compositions which have the same action as GLP-1 peptide as a GLP-1 receptor agonist, are capable of noninvasive administration, and contain a compound having improved activity, metabolic stability, and bioavailability or a salt thereof or a solvate thereof, and to provide methods for preventing or treating non-insulin-dependent diabetes mellitus or obesity using the pharmaceutical compositions.SOLUTION: The present invention provides a pharmaceutical composition which contains as active ingredient a compound having a base skeleton represented by formula (I) in which an indole ring and a pyrazolopyridine skeleton are linked via a substituent, or a salt thereof or a solvate thereof, and is used in the prevention and treatment of non-insulin-dependent diabetes mellitus (type 2 diabetes mellitus) or obesity.SELECTED DRAWING: None
Owner:CHUGAI PHARMA CO LTD

Aromatic propionic acid derivative as well as preparation method, pharmaceutical composition and application thereof

The invention discloses an aromatic propionic acid derivative as well as a preparation method, a pharmaceutical composition and application thereof. The invention specifically discloses a compound shown in a formula (I) or pharmaceutically acceptable salt thereof. The invention further discloses a pharmaceutical composition which comprises the compound shown in the formula (I), pharmaceutically acceptable salt of the compound and pharmaceutic adjuvants. The invention also discloses application of the compound as shown in the formula (I), the pharmaceutically acceptable salt of the compound or the pharmaceutical composition in preparation of drugs, and the drugs have GPR40 receptor agonistic activity and have one or more of the advantages of good activity, high targeting property, low toxicity and the like. # imgabs0 #
Owner:SUZHOU VINCENTAGE PHARMA CO LTD

GLP-1 co-agonists and their associated prodrugs

Peptides exhibiting GIP and GLP-1 receptor agonist activity, as well as prodrug derivatives thereof, are provided. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods for using such peptides are also provided.
Owner:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP

Heterocyclic compound and use thereof

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

1-[[(3S)-3-methyl-6-(4(4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2yl]methyl]azetidine-3-carboxylic acid having s1p5 receptor agonist activity for the treatment of neurodegenerative disorders and cancer

Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the SIPi receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases. This compound represented by general formula (V) (in the formula, all symbols are as defined in the specification) has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic for SIPs-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
Owner:ONO PHARMA CO LTD

Heterocyclic compound and use thereof

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

Oxazepin Derivative

Novel compounds are provided with excellent orexin type 2 receptor agonist activity. The compounds are represented by Formula (I) or pharmaceutically acceptable salts thereof.
Owner:TEIJIN PHARMA CO LTD

RXFP1 receptor agonist and preparation method and application thereof

The invention belongs to the technical field of chemical drugs, and provides an RXFP1 receptor agonist and a preparation method and application thereof, and the compound provided by the invention has good RXFP1 receptor agonist activity and can be used for treating heart failure. # imgabs0 #
Owner:SHENZHEN SALUBRIS PHARMA CO LTD

Heterocyclic compound

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

A class of benzo[nitrogen-containing heterocyclic] derivatives and their applications

This invention belongs to the field of medicinal chemistry, specifically relating to a class of benzo[a]nitrogen-containing heterocyclic derivatives and their applications. This invention provides a class of benzo[a]nitrogen-containing heterocyclic derivatives having the structure shown in formula (I), including their stereoisomers, their isotopically substituted compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing such derivatives. These benzo[a]nitrogen-containing heterocyclic derivatives exhibit significant glucagon-like peptide-1 (GLP-1) receptor agonist activity, while also demonstrating excellent metabolic stability, a favorable half-life, and good in vivo exposure. These properties help to prolong dosing intervals, improve patient compliance, maintain more stable blood drug concentrations, and improve tolerability, laying a solid foundation for their application in the preparation of drugs for the prevention and / or treatment of GLP-1-related diseases, and possessing broad prospects for clinical development.
Owner:ZHUZHOU QIANJIN PHARMA

Heterocyclic compounds

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. Formula (I): JPEG2024545515000096.jpg46118 [In the formula, each symbol is as defined in the specification.] or a salt thereof is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

Indolinyl-methylene thiazolidinedione derivatives and uses thereof

PendingCN123026612ADiseaseSide effect
The application discloses an indolylmethylthiazolidinedione derivative and application thereof. The application provides a novel structure of indolylmethylthiazolidinedione derivative by performing specific structure modification on an indolylmethylthiazolidinedione nucleus. The in-vitro pharmacological test verifies that the compound has high CB2 receptor subtype selectivity, excellent CB2 receptor agonist activity and broad-spectrum anti-tumor proliferation activity, and has a significant inhibiting effect on leukemia, multiple myeloma, liver cancer, glioma and various tumor cells. The compound has excellent drug property and low side effect risk, can be used as a new CB2 specific agonist candidate drug, and has a good application prospect and research and development value in the development of drugs for treating related diseases such as anti-tumor, anti-inflammatory, immune regulation and nerve protection.
Owner:HUZHOU UNIVERSITY

GIP / GLP-1 co-agonists and their associated prodrugs

Peptides that exhibit GIP and GLP-1 receptor agonist activity are provided as well as prodrug derivative thereof. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided.
Owner:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP

Heterocyclic compound and use thereof

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

Heterocyclic compound

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. A compound represented by formula (I): wherein each symbol is as described in the specification, or a salt thereof, useful as an agent for preventing or treating narcolepsy.
Owner:TAKEDA PHARMA CO LTD

Pharmaceutical composition containing GLP-1 receptor agonist having fused ring

The present invention relates to a compound that has GLP-1 receptor agonist activity and is useful as a therapeutic or prophylactic agent for diseases associated with the GLP-1 receptor, or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition containing the compound or its pharmaceutically acceptable salt.Provided is a compound represented by formula (I):wherein A1 is C(R5) or the like, A2 is C(R6) or the like, A3 is C(R7) or the like, R5, R6, and R7 are each independently a hydrogen atom or the like, R1 is carboxy or the like, R2 is substituted or unsubstituted alkyl or the like, —X— is —O— or the like, the ring represented by:is a ring represented by: and the likewhereinR10 is each independently halogen or the like,s is 0 or the like,R13 is each independently a hydrogen atom or the like, and R3 is substituted or unsubstituted aromatic carbocyclyl or the like, ora pharmaceutically acceptable salt thereof.
Owner:SHIONOGI & CO LTD

Heterocyclic compound

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. A compound represented by formula (I): # imgabs0 # wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for preventing or treating narcolepsy.
Owner:TAKEDA PHARMA CO LTD

Heterocyclic compound and use thereof

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

Phenethylamines and methods of preparation thereof

The present disclosure relates to compounds of Formula I that exhibit 5-HT2A receptor agonist activity and low 5HT2B receptor agonist activity or deemed 5HT2B receptor agonist inactivity. In at least some cases, such compounds show selectivity for the 5-HT2A receptor over the 5-HT2C receptor. As contemplated herein, phenethylamines may be used for the treatment of neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders including depression, drug (e.g. tobacco, opiate, and cocaine) addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.
Owner:BRIGHT MINDS BIOSCIENCES INC

Polyamide compounds, methods for preparing the same, and their pharmaceutical use

This invention provides a novel κ-opioid receptor (KOR receptor) agonist compound that exhibits excellent efficacy and action. [Solution] In one embodiment, a compound represented by formula IB, its stereoisomer, or a pharmaceutically acceptable salt thereof is provided. Such novel amide bond-containing compounds not only have excellent KOR receptor agonist activity (high affinity for κ opioid receptors), but also have very good hydrophilicity, and therefore have a lower ability to cross the blood-brain barrier and enter the brain. JPEG2026086406000232.jpg3368
Owner:チアンスー エヌエイチダブリュエー ファーマシューティカル カンパニー リミテッド

Heterocyclic compounds and their uses

The present invention provides heterocyclic compounds having orexin type 2 receptor agonist activity. Formula (I): JPEG2025539434000134.jpg51127 [wherein each symbol is as defined in the specification] The compound or a salt thereof has orexin type 2 receptor agonist activity and is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

GIP / GLP-1 co-agonists and their associated prodrugs

Peptides that exhibit GIP and GLP-1 receptor agonist activity are provided as well as prodrug derivative thereof. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided.
Owner:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP

Heterocyclic compound and use thereof

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

Tryptamine prodrugs

The present invention provides a tryptamine prodrug compound. A compound represented by the formula (I)where each symbol is as described in the specification, or a salt or zwitterion thereof, is converted to an active which has 5HT2A receptor agonist activity, and is useful as an agent for the treatment of depression.
Owner:REUNION NEUROSCIENCE INC

Tryptamine prodrugs

The invention provides a tryptamine prodrug compound. A compound represented by structural formula (I) wherein each symbol is as described in the specification, or a salt or zwitterion thereof, converted into an active agent having 5HT2A receptor agonist activity, and useful as an agent for the treatment of depression
Owner:REUNION NEUROSCIENCE INC

Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

Heterocyclic compound and use thereof

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I): # imgabs0 # wherein each symbol is as described in the specification, or a salt thereof, which has orexin type 2 receptor agonist activity and is useful as an agent for preventing or treating hypersomnia.
Owner:TAKEDA PHARMA CO LTD